Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns - 23/09/16

on behalf of the
Trial of Late Surfactant (TOLSURF) Study Group*
Abstract |
Objective |
To assess the prognostic accuracy of early cumulative supplemental oxygen (CSO) exposure for prediction of bronchopulmonary dysplasia (BPD) or death, and to evaluate the independent association of CSO with BPD or death.
Study design |
We performed a secondary analysis of the Trial of Late Surfactant, which enrolled 511 infants born at ≤28 weeks gestational age who were mechanically ventilated at 7-14 days of life. Our primary outcome was BPD or death at 36 weeks postmenstrual age, as determined by a physiological oxygen/flow challenge. Average daily supplemental oxygen (fraction of inspired oxygen - 0.21) was calculated. CSO was calculated as the sum of the average daily supplemental oxygen over time periods of interest up to 28 days of age. Area under the receiver operating curve (AUROC) values were generated to evaluate the accuracy of CSO for prediction of BPD or death. The independent relationship between CSO and BPD or death was assessed in multivariate modeling, while adjusting for mean airway pressure.
Results |
In the study infants, mean gestational age at birth was 25.2 ± 1.2 weeks and mean birth weight was 700 ± 165 g. The AUROC value for CSO at 14 days was significantly better than that at earlier time points for outcome prediction (OR, 0.70; 95% CI, 0.65-0.74); it did not increase with the addition of later data. In multivariate modeling, a CSO increase of 1 at 14 days increased the odds of BPD or death (OR, 1.7; 95% CI, 1.3-2.2; P < .0001), which corresponds to a 7% higher daily supplemental oxygen value.
Conclusion |
In high-risk extremely low gestational age newborns, the predictive accuracy of CSO plateaus at 14 days. CSO is independently associated with BPD or death. This index may identify infants who could benefit from early intervention to prevent BPD.
Le texte complet de cet article est disponible en PDF.Keywords : inhaled nitric oxide, mechanical ventilation, oxidative stress, prematurity, surfactant
Abbreviations : AUROC, BPD, CSO, ELGAN, FiO2, GA, iNO, MAP, PMA, TOLSURF
Plan
| TOLSURF was funded by the National Heart, Lung, and Blood Institute (U01HL094338 and U01HL094355). ONY, Inc provided Infasurf and IKARIA, Inc provided inhaled nitric oxide and its delivery system for the conduct of the study. K.W. was supported by the National Center for Advancing Translational Sciences, National Institutes of Health through University of California, San Francisco-Clinical and Translational Science Institute (UL1 TR000004). The authors declare no conflicts of interest. |
Vol 177
P. 97 - octobre 2016 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?
